Abstract.
Israeli Jewish women are at low risk for cancer of the uterine cervix. In view of absent screening programs in Israel, there are only scarce data available with regard to results of PAP smears. The aim of this study was to assess the incidence of premalignant cervical lesions in the largest sample of PAP smears reported so far from Israel. We retrospectively analyzed the results of 297,849 PAP smears, which had been examined in a single laboratory, during 9 years (1991–1999). The incidence of low- and high-grade squamous intraepithelial was 0.69% and 0.29%, respectively. Our data indicate similar incidence rates for premalignant lesions in Jewish Israeli women as observed in Western countries, but no increase during the study period. In spite of relatively high incidence rates for premalignant lesions of the uterine cervix, the incidence rate for invasive cervical cancer remains conspicuously low. For unknown reason the conversion rate from premalignant cervical lesions to invasive cancer is lower in Israeli Jewish women than in European and North American women. We discuss possible reasons for this phenomenon and suggest that at this time mass screening for cervical cancer in Israel may probably not be justified.
Similar content being viewed by others
References
Bar-Am A, Niv J, Yavetz H, Jaffa AJ, Peyser RM (1995) Are Israeli women in a low risk group for developing squamous cell carcinoma of the uterine cervix? Acta Obstet Gynecol Scand 74:472–477
Broder S (1992) From the National Institutes of Health. The Bethesda system for reporting cervical/vaginal cytological diagnosis. Report of 1991 workshop. JAMA 267:1892
Committee on Gynecologic Practice (1995) Recommendations on frequency of PAP test screening. ACOG committee opinion no 152
Glezerman M, Piura B, Insler V (1989) Cervical cancer in Jewish women. Am J Obstet Gynecol 161:1186–1190
Helfand M, O’Connor GT, Zimmer-Gembeck M (1992) Effect of the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) on the incidence of invasive cervical cancer. Med Care 30:1067–1082
Magnusson PKE, Sparen P, Gyllensten UB (1999) Genetic link to cervical tumors. Nature 400:29–30
Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA (1999) Identifying women with cervical neoplasia using human papilloma virus NA testing for equivocal Papanicolaou results. JAMA 281:1605–1610
Menczer J, Fintsi Y, Arbel-Alon S, Tell L, Friedman E, Jackman A, Sherman L (2000) The presence of HPV 16:18 and p53 immunohistochemical staining in tumor tissue of Israeli Jewish women with cervical and vulvar neoplasia. Eur J Gynaecol Oncol 21:30–34
Parkin DM, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594–606
Ponten J, Adami HO, Bergstrom R, Dillner J, Friberg LG, Gustafsson L, Miller AB, Parkin DM, Sparen P, Trichopoulos D (1995) Strategies for global control of cervical cancer. Int J Cancer 60:1–26
Ries L, Miller B, Haskey B (1994) SEER cancer statistic review 1973–1991, National Cancer Institute publ no 94-2789
Schachter A, Avraham E (1984) Changing trends of cervical neoplasia in Israeli Jews. Lancet II:1150
van Duin M, Snijders PJ, Vossen MT, Klaassen E, Voorhorst F, Verheijen RH, Helmerhorst TJ, Meijer CJ, Walboomers JM (2000) Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 81:317–325
Acknowledgements.
We express our gratitude to J. and J. Ronen, chairmen of Care-Med Laboratories for allowing us access to the cytological data.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sadan, O., Schejter, E., Ginath, S. et al. Premalignant lesions of the uterine cervix in a large cohort of Israeli Jewish women. Arch Gynecol Obstet 269, 188–191 (2004). https://doi.org/10.1007/s00404-002-0371-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-002-0371-y